Molecular markers of chemotherapeutic response and toxicity in colorectal cancer

Outcomes in colorectal cancer have improved over the last 15 years; this is in part due to the optimization of 5-fluorouracil schedules and the introduction of new and effective chemotherapeutic agents, such as irinotecan and oxaliplatin. However, not all patients respond to these agents and a propo...

Full description

Saved in:
Bibliographic Details
Published inExpert review of anticancer therapy Vol. 7; no. 4; pp. 489 - 501
Main Authors Braun, Michael S, Quirke, Philip, Seymour, Matthew T
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 01.04.2007
Informa Healthcare
Subjects
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
colorectal
Colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Colorectal Neoplasms - metabolism
fluorouracil
Humans
irinotecan
molecular marker oxaliplatin
Online AccessGet full text

Cover

More Information
Summary:Outcomes in colorectal cancer have improved over the last 15 years; this is in part due to the optimization of 5-fluorouracil schedules and the introduction of new and effective chemotherapeutic agents, such as irinotecan and oxaliplatin. However, not all patients respond to these agents and a proportion may suffer severe side effects from particular chemotherapy drugs. These observations have resulted in a concerted research effort to identify markers of chemotherapy efficacy and toxicity. Here we review the evidence for using molecular markers to individualize chemotherapy treatment in colorectal cancer.
ISSN:1473-7140
1744-8328
DOI:10.1586/14737140.7.4.489